NCT04080804 2026-02-09
Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer
University of Pittsburgh
Phase 2 Recruiting
University of Pittsburgh
University of Pittsburgh